Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 6,453 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward Md Kaye sold 6,453 shares of the company’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $30.87, for a total transaction of $199,204.11. Following the completion of the sale, the director owned 71,102 shares of the company’s stock, valued at $2,194,918.74. This represents a 8.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $30.87 on Friday. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $38.69. The stock’s 50-day moving average is $29.03 and its two-hundred day moving average is $19.83. The firm has a market cap of $1.76 billion, a P/E ratio of 46.07 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The company had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. On average, equities analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on STOK shares. Wedbush increased their price target on Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. BTIG Research reaffirmed a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Stoke Therapeutics in a report on Monday. Chardan Capital upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Finally, JPMorgan Chase & Co. lifted their price objective on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a research note on Monday, November 3rd. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics has a consensus rating of “Buy” and a consensus target price of $31.00.

Institutional Trading of Stoke Therapeutics

A number of hedge funds have recently bought and sold shares of STOK. Generali Investments Management Co LLC acquired a new stake in Stoke Therapeutics in the 3rd quarter worth $41,000. BNP Paribas Financial Markets lifted its stake in shares of Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares during the period. AlphaQuest LLC acquired a new stake in Stoke Therapeutics during the first quarter worth about $72,000. Finally, US Bancorp DE increased its stake in Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after acquiring an additional 11,108 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.